Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (March 2021)
21 slides from Cynata Therapeutics's investor presentation, Mar 12, 2021
Slide 1: Cynata Investor Presentation ASX Announcement
ASX ANNOUNCEMENT 12 March 2021 For personal use only Cynata Investor Presentation Melbourne, Australia; 12 March 2021: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to release a Corporate Investor Presentation that will b
Slide 2: A Next Generation Stem Cell Therapeutics Company
For personal use only A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited March 2021
Slide 3: Important information
Important information Summary information ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, ‘potential’ and other similar This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries expressions. The forward looking statem
Slide 4: Key recent highlights
✓ Key recent highlights For personal use only Commencement of Commencement of Phase 2 GvHD Phase 1 results osteoarthritis Phase 3 clinical COVID-19 trial & assessment of published in prestigious journal, trial, funded by a NHMRC grant options to accelerate recruitment Nature Medicine MoU signed with
Slide 5: Company overview
Company overview Cynata is a clinical stage biotech developing its proprietary CymerusTM platform technology for the scalable manufacture of mesenchymal stem cell (MSC) therapeutic products to treat serious disorders For personal use only About Cynata Therapeutics Financial information ▪ Stem cell a
Slide 6: Cynata well placed in the regenerative medicine market
Cynata well placed in the regenerative medicine market Cynata is at the forefront of stem cell technology and ideally placed as global interest continues to grow in MSCs For personal use only Global interest in MSCs continues to grow Key driver of shareholder value for Cynata is ultimately the Cymer
Slide 7: Conventional vs. Cynata's Cymerus MSC manufacturing process
Conventional vs. Cynata’s Cymerus MSC manufacturing process Cells donated Conventional process MSCs For personal use only The current Cells from MSC isolation MSC expansion Cell therapy product multiple donors conventional manufacturing process is sub optimal Substantial variability Limited quantity
Slide 8: FDA focus on manufacturing
FDA focus on manufacturing Cynata’s Cymerus process actively addresses some of the key areas that the FDA is likely to focus on For personal use only Potential issues raised Key advantages underpinning Cymerus ✓ “The issue of reliable prediction of Product derived from a single donor provides a high
Slide 9: Phase 1 clinical trial results (CYP-001)
Phase 1 clinical trial results (CYP-001) Outstanding results in the world-first allogeneic iPSC-derived therapy trial in steroid-resistant acute graft- versus-host disease (GvHD) places Cynata in a strong position to accelerate clinical development For personal use only Key clinical trial results1 -
Slide 10: Cymerus platform
Cymerus platform Cynata's Cymerus platform has potential applications across a wide range of diseases For personal use only Crohn’s Disease Others Osteoarthritis (funded by NHMRC) Fistula Coronary Artery Disease Potential future Phase 3 target areas Underway Heart attack Pre- clinical Brain cancer /
Slide 11: SCUlpTOR | Osteoarthritis Phase 3 clinical trial
SCUlpTOR1 | Osteoarthritis Phase 3 clinical trial Clinical trial underway, sponsored by the University of Sydney and funded by an NHMRC project grant For personal use only Significant opportunity ▪ Osteoarthritis occurs when the protective layer between bones (cartilage) in a joint wears away, which
Slide 12: SCUlpTOR | Osteoarthritis trial underway
SCUlpTOR1 | Osteoarthritis trial underway Recruitment has commenced, seeking to enrol 440 patients with osteoarthritis of the knee to participate in the randomised, double-blind placebo-controlled phase 3 clinical trial For personal use only Initial safety Four week safety follow-up of initial patie
Slide 13: Clinical Trial: Diabetic foot ulcers
Clinical Trial: Diabetic foot ulcers Plans to undertake a clinical trial based on a solid pre-clinical foundations and utilising TekCyte technology For personal use only Diabetic Foot Sores on the feet of patients with diabetes that occur in ~15-25% Ulcers (DFU) of patients sometime during their lif
Slide 14: Expanding the clinical development pipeline
Expanding the clinical development pipeline Further Priority Indications, with preparations for clinical trials underway For personal use only Idiopathic pulmonary fibrosis Renal transplantation Incurable disease of unknown cause, which results in Treatment for end-stage kidney disease, where the Di
Slide 15: Multiple options to create shareholder value
Multiple options to create shareholder value Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to optimise shareholder value For personal use only Build value in platform License / partner Strategic exit / independently with big Pharma merger Clinical
Slide 16: Significant market opportunities
Significant market opportunities Cynata is targeting attractive market opportunities across a range of target indications For personal use only Target area Trial Phase Market opportunity 1 Osteoarthritis (OA) Phase 3 underway US$11.6 bn Graft vs. Host Disease (GvHD) Phase 2 planning US$0.6 bn 2 Acut
Slide 17: Valuation upside
Valuation upside Significant upside potential for Cynata when compared to other stem cell-therapy companies US$8.80bn3 For personal use only Significant upside potential for Cynata US$1.00bn2 US$1.15bn1 Market Capitalisation: US$0.07bn1 Company GvHD: Phase 1 complete Clinical stage Parkinson’s disea
Slide 18: Development pipeline and outlook
Development pipeline and outlook Broad and advanced clinical development pipeline, with multiple active trials and near-term catalysts For personal use only Pre-clinical Phase 1 Phase 2 Phase 3 Key catalysts Fujifilm responsible for all updates and ongoing GvHD development via global license agreeme
Slide 19: Key objectives for 2021
Key objectives for 2021 Cynata is in a strong position going forward with ~A$30m cash1 to fund all planned clinical trials and advance development of its proprietary Cymerus platform technology For personal use only Execute on the expansion of the clinical pipeline and commence new clinical trials E
Slide 20: Investment summary
Investment summary Scalable stem • Patented Cymerus platform technology enables commercial-scale production of mesenchymal stem cells from a single donor, For personal use only cell therapy overcoming multiple issues with today’s on-market solutions technology • Value of platform to a range of disea
Slide 21: Contact details
For personal use only Cynata Therapeutics Limited Contact details: Level 3 62 Lygon Street ross.macdonald@cynata.com Carlton Victoria 3053 www.cynata.com Australia
Cynata Therapeutics — Investor Presentation (March 2021) on 6ix